JP2021516256A - Cd19に基づくキメラ抗原受容体及びその利用 - Google Patents
Cd19に基づくキメラ抗原受容体及びその利用 Download PDFInfo
- Publication number
- JP2021516256A JP2021516256A JP2020568017A JP2020568017A JP2021516256A JP 2021516256 A JP2021516256 A JP 2021516256A JP 2020568017 A JP2020568017 A JP 2020568017A JP 2020568017 A JP2020568017 A JP 2020568017A JP 2021516256 A JP2021516256 A JP 2021516256A
- Authority
- JP
- Japan
- Prior art keywords
- chimeric antigen
- antigen receptor
- domain
- cells
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 90
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 title claims abstract description 54
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 title claims abstract description 54
- 210000004027 cell Anatomy 0.000 claims abstract description 100
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 44
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 30
- 239000000427 antigen Substances 0.000 claims abstract description 30
- 108091007433 antigens Proteins 0.000 claims abstract description 30
- 102000036639 antigens Human genes 0.000 claims abstract description 30
- 230000011664 signaling Effects 0.000 claims abstract description 30
- 230000004927 fusion Effects 0.000 claims abstract description 14
- 206010010144 Completed suicide Diseases 0.000 claims abstract description 13
- 230000001939 inductive effect Effects 0.000 claims abstract description 13
- 239000013598 vector Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 17
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 17
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 14
- 241000713666 Lentivirus Species 0.000 claims description 13
- 102100027207 CD27 antigen Human genes 0.000 claims description 11
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 150000007523 nucleic acids Chemical group 0.000 claims description 9
- 239000013603 viral vector Substances 0.000 claims description 7
- 230000004068 intracellular signaling Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000003248 secreting effect Effects 0.000 claims description 6
- 230000019491 signal transduction Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 230000001613 neoplastic effect Effects 0.000 claims description 4
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 230000008622 extracellular signaling Effects 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000013613 expression plasmid Substances 0.000 claims description 2
- 230000031146 intracellular signal transduction Effects 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 238000010361 transduction Methods 0.000 claims description 2
- 230000026683 transduction Effects 0.000 claims description 2
- 230000002147 killing effect Effects 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 14
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 230000001900 immune effect Effects 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 238000012239 gene modification Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 108010005327 CD19-specific chimeric antigen receptor Proteins 0.000 description 24
- 229940088592 immunologic factor Drugs 0.000 description 16
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 11
- 102000004039 Caspase-9 Human genes 0.000 description 11
- 108090000566 Caspase-9 Proteins 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 230000004044 response Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108090000672 Annexin A5 Proteins 0.000 description 3
- 102000004121 Annexin A5 Human genes 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000000367 immunologic factor Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000011357 CAR T-cell therapy Methods 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 108700010039 chimeric receptor Proteins 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000008791 toxic response Effects 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
前記抗原結合ドメインは腫瘍表面抗原に結合し、前記抗原結合ドメインは腫瘍表面抗原CD19に対する一本鎖抗体であり、前記共刺激シグナル伝達領域はCD27シグナル伝達ドメインを含み、かつ前記誘導性自殺融合ドメインはiCasp9である、キメラ抗原受容体を提供する。
DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSS
QRRKYRSNKGESPVEPAEPCHYSCPREEEGSTIPIQEDYRKPEPACSP
GSGATNFSLLKQAGDVEENPGPMGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKVDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGGGSGGGGSGAMVGALESLRGNADLAYILSMEPCGHCLIINNVNFCRESGLRTRTGSNIDCEKLRRRFSSLHFMVEVKGDLTAKKMVLALLELARQDHGALDCCVVVILSHGCQASHLQFPGAVYGTDGCPVSVEKIVNIFNGTSCPSLGGKPKLFFIQACGGEQKDHGFEVASTSPEDESPGSNPEPDATPFQEGLRTFDQLDAISSLPTPSDIFVSYSTFPGFVSWRDPKSGSWYVETLDDIFEQWAHSEDLQSLLLRVANAVSVKGIYKQMPGCFNFLRKKLFFKTSAS
IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP
FWVLVVVGGVLACYSLLVTVAFIIFWV
RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSAS
MLLLVTSLLLCELPHPAFLLIP
MALPVTALLLPLALLLHAARP
MLLLVTSLLLCELPHPAFLLIP
分泌−CD19−CD28−CD27−CD3ζ−2A−iCasp9
MLLLVTSLLLCELPHPAFLLIPDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSASGGGGSGGGGSQRRKYRSNKGESPVEPAEPCHYSCPREEEGSTIPIQEDYRKPEPACSPGGGGSGGGGSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRTSGSGATNFSLLKQAGDVEENPGPMGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKVDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGGGSGGGGSGAMVGALESLRGNADLAYILSMEPCGHCLIINNVNFCRESGLRTRTGSNIDCEKLRRRFSSLHFMVEVKGDLTAKKMVLALLELARQDHGALDCCVVVILSHGCQASHLQFPGAVYGTDGCPVSVEKIVNIFNGTSCPSLGGKPKLFFIQACGGEQKDHGFEVASTSPEDESPGSNPEPDATPFQEGLRTFDQLDAISSLPTPSDIFVSYSTFPGFVSWRDPKSGSWYVETLDDIFEQWAHSEDLQSLLLRVANAVSVKGIYKQMPGCFNFLRKKLFFKTSAS、又は本出願によれば、分泌−CD19−CD28−CD27−CD3ζ−2A−iCasp9(4S−CAR19)のキメラ抗原受容体は、配列番号5に示される核酸配列又は該核酸配列に対して80%を超えるホモロジーを有する核酸配列を有する。配列番号5に示される核酸配列は以下の通りである:
ATGCTGCTGCTGGTCACAAGCCTGCTGCTGTGCGAGCTGCCCCACCCCGCCTTTCTGCTGATCCCCGACATCCAGATGACCCAGACCACCAGCAGCCTGAGCGCCAGCCTGGGCGACAGAGTGACCATCAGCTGCCGGGCCAGCCAGGACATCAGCAAGTACCTGAACTGGTATCAGCAGAAACCCGACGGCACCGTGAAGCTGCTGATCTACCACACCAGCCGGCTGCACAGCGGCGTGCCCAGCAGATTTTCTGGCAGCGGATCTGGCACCGACTACAGCCTGACCATCTCCAACCTGGAACAGGAAGATATCGCTACCTACTTCTGTCAGCAGGGCAACACCCTGCCCTACACCTTCGGCGGAGGCACCAAGCTGGAAATCACCGGCAGCACCAGCGGCTCCGGCAAGCCTGGATCTGGCGAGGGCAGCACCAAGGGCGAAGTGAAGCTGCAGGAAAGCGGCCCTGGCCTGGTCGCCCCTAGCCAGAGCCTGTCCGTGACCTGTACCGTGTCCGGCGTGTCCCTGCCCGACTACGGCGTGTCCTGGATCAGACAGCCCCCCAGAAAGGGCCTGGAATGGCTGGGCGTGATCTGGGGCAGCGAGACAACCTACTACAACAGCGCCCTGAAGTCCCGGCTGACCATCATCAAGGACAACAGCAAGAGCCAGGTGTTCCTGAAGATGAACAGCCTGCAGACCGACGACACCGCCATCTACTACTGCGCCAAGCACTACTACTACGGCGGCAGCTACGCCATGGACTACTGGGGCCAGGGCACCAGCGTGACAGTCTCTTCTGCGGCCGCAATTGAAGTTATGTATCCTCCTCCTTACCTAGACAATGAGAAGAGCAATGGAACCATTATCCATGTGAAAGGGAAACACCTTTGTCCAAGTCCCCTATTTCCCGGACCTTCTAAGCCCTTTTGGGTGCTGGTGGTGGTTGGGGGAGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCTGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGCTAGCGGAGGTGGAGGTTCTGGAGGTGGTGGAAGTCAAAGAAGGAAGTACCGCAGCAACAAAGGAGAATCTCCCGTCGAGCCAGCCGAGCCCTGTCATTATTCATGCCCAAGGGAGGAGGAGGGAAGTACAATCCCAATTCAAGAAGACTACAGGAAGCCCGAACCTGCATGCAGTCCAGGTGGAGGCGGTTCTGGAGGCGGTGGCTCCCGGGTGAAATTCTCACGGTCTGCAGACGCACCCGCTTACCAGCAAGGCCAGAACCAACTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGCACTAGTGGCTCCGGAGCCACGAACTTCTCTCTGTTAAAGCAAGCAGGAGACGTGGAAGAAAACCCCGGTCCCATGGGAGTGCAGGTGGAAACCATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCGCGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGAAAGTGGACTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAAGCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGGGTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTGGGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGCTTCTAAAACTGGAAGGTGGAGGCGGTTCAGGCGGCGGCGGCAGCGGCGCCATGGTCGGTGCTCTTGAGAGTTTGAGGGGAAATGCAGATTTGGCTTACATCCTGAGCATGGAGCCCTGTGGCCACTGCCTCATTATCAACAATGTGAACTTCTGCCGTGAGTCCGGGCTCCGCACCCGCACTGGCTCCAACATCGACTGTGAGAAGTTGCGGCGTCGCTTCTCCTCGCTGCATTTCATGGTGGAGGTGAAGGGCGACCTGACTGCCAAGAAAATGGTGCTGGCTTTGCTGGAGCTGGCGCGGCAGGACCACGGTGCTCTGGACTGCTGCGTGGTGGTCATTCTCTCTCACGGCTGTCAGGCCAGCCACCTGCAGTTCCCAGGGGCTGTCTACGGCACAGATGGATGCCCTGTGTCGGTCGAGAAGATTGTGAACATCTTCAATGGGACCAGCTGCCCCAGCCTGGGAGGGAAGCCCAAGCTCTTTTTCATCCAGGCCTGTGGTGGGGAGCAGAAAGACCATGGGTTTGAGGTGGCCTCCACTTCCCCTGAAGACGAGTCCCCTGGCAGTAACCCCGAGCCAGATGCCACCCCGTTCCAGGAAGGTTTGAGGACCTTCGACCAGCTGGACGCCATATCTAGTTTGCCCACACCCAGTGACATCTTTGTGTCCTACTCTACTTTCCCAGGTTTTGTTTCCTGGAGGGACCCCAAGAGTGGCTCCTGGTACGTTGAGACCCTGGACGACATCTTTGAGCAGTGGGCTCACTCTGAAGACCTGCAGTCCCTCCTGCTTAGGGTCGCTAATGCTGTTTCGGTGAAAGGGATTTATAAACAGATGCCTGGTTGCTTTAATTTCCTCCGGAAAAAACTTTTCTTTAAAACATCAGCTAGT
(1)T細胞キメラ受容体遺伝子の特定の改変とT細胞シグナル伝達領域の最適化及び改変とによって、本出願のキメラ抗原受容体はより優れた殺傷効果を発揮することができ、免疫因子ストームを簡単には引き起こさず、安全な除去メカニズムを伴う。これらの改変により、キメラ抗原受容体CD19細胞のより効果的で幅広い安全な利用が可能となる。
(2)白血病及びリンパ腫において高度に発現されるCD19を標的とする本出願のキメラ抗原受容体は、腫瘍表面抗原を特異的に認識することができる。さらに、該キメラ抗原受容体は、腫瘍表面抗原CD19を認識した後に、穏やかで効果的な応答を引き起こすため、該キメラ抗原受容体は他のキメラ抗原受容体よりも安全な効果を有し、こうしてCAR−T細胞の免疫効果だけでなく、CAR−T細胞の安全性も高められる。
(1)図1に示される、分泌シグナルペプチド、CD19抗原結合ドメイン、CD8α及び/又はCD28膜貫通ドメイン、CD28シグナル伝達ドメイン、CD27シグナル伝達ドメイン、CD3ζシグナル伝達ドメイン、2A配列、並びにカスパーゼ9ドメイン、すなわち、分泌−CD19−CD28−CD27−CD3ζ−2A−iCasp9を、遺伝子合成によって化学的に合成した。
(1)293T細胞を使用して、17時間〜18時間培養した。
(2)10%FBSを含有する新たなDMEMを添加した。
(3)滅菌遠心チューブに以下の試薬を添加した:各ウェルにDMEMを取り、ヘルパーDNAミックス(pNHP、pHEF−VSV−G)及びpTYF DNAベクターを添加し、ボルテックスして、振盪した。
(4)Superfect又は任意のトランスジェニック材料を遠心チューブに添加し、室温で7分間〜10分間放置した。
(5)各培養細胞に、遠心チューブ内のDNA−Superfect混合物を添加し、ボルテックスして、混合した。
(6)3%のCO2インキュベーター内にて37℃で4時間〜5時間培養した。
(7)培養培地から上清を抜き取り、培養物を293細胞培地ですすぎ、更なる培養のために培地を添加した。
(8)培養物を5%のCO2インキュベーターに戻して、一晩培養した。翌朝及び翌日に、妥当であれば蛍光顕微鏡を用いてトランスフェクション効率を観察した。
1)ウイルスの精製
細胞片を1000gで5分間の遠心分離により除去して、ウイルス上清を得た。ウイルス上清を0.45μm低タンパク質結合フィルターで濾過し、ウイルスを小分けにして、−80℃で貯蔵した。
(1)ウイルス上清をCentriconフィルターチューブに添加した後に、2500gで30分間遠心分離した。
活性化させたT細胞を培養皿に播種し、標的抗原に対する特異性を有する濃縮されたレンチウイルスを添加し、100gの遠心力速度で100分間遠心分離(スピノキュレーション)し、37℃で24時間培養し、そして細胞培養因子を含むAIM−V培地を添加し、2日間〜3日間の培養の後に、細胞を採取し、計数することで、利用可能なCD19 CAR−T細胞を得た。
(1)図2(a)及び図2(b)から、CD19が初代骨髄B−ALL細胞の表面上で高度に発現され、B−ALL患者において広く発現されたことが分かり、本出願で使用するために選択されたCD19キメラ抗原受容体をB−ALLの治療に使用することができることが示唆される。
(1)41BB CAR19、28−27 CAR19及び本出願の28−27 Caspase9 CAR19(4S−CAR19)を含む、異なるシグナル伝達ドメインを備えた非特異的T細胞又はCD19 CAR−T細胞を、RS4−11と一緒に5%のCO2インキュベーター内にて37℃で24時間共培養した。培養の2時間後、6時間後及び24時間後に、生きているRS4−11細胞のパーセンテージを記録し、これらの結果を図4(a)に示した。41BB CAR19、28−27 CAR19及び本出願の28−27 Caspase9 CAR19は、コントロール群のT細胞と比較してRS4−11細胞に対して有意な殺傷効果を有した。培養の2時間後及び6時間後に得られたデータから分かるように、本出願の28−27 Caspase9 CAR19は、培養の24時間後に比較的遅い殺傷動態を有したが、41BB CAR19及び28−27 CAR19と同じ殺傷効果が達成された。本出願の28−27 Caspase9 CAR19によって引き起こされる白血病細胞の除去により、臨床用途において重篤な毒性応答(サイトカイン放出症候群、CRS)が誘発されないことが示された。
本研究所は、2013年7月から2016年7月まで22の臨床医療センター及び病院と協力して研究し、登録基準を満たすCD19陽性で化学療法耐性のB−ALL患者102人を治療し、注意深く追跡した。合計55人の小児及び47人の成人がおり、そのうち27人が同種造血幹細胞移植を受けていた。これらの患者は、CAR−Tを投与した時点で骨髄中の初期白血病芽細胞の中央値パーセンテージ14.5%(0%〜98%の範囲)を有していた。これらの患者のうち、69人の患者は、50%未満の骨髄中の初期白血病芽球を有し、他の33人の患者は50%超の骨髄中の白血病芽球を有していた。初期診断からCAR−T細胞療法までの中央値期間は17ヶ月(2ヶ月〜164ヶ月)であった。
Claims (15)
- 抗原結合ドメインと、膜貫通ドメインと、共刺激シグナル伝達領域と、CD3ζシグナル伝達ドメインと、誘導性自殺融合ドメインとをタンデム配置で含むCD19に基づくキメラ抗原受容体であって、
前記抗原結合ドメインは腫瘍表面抗原に結合し、前記抗原結合ドメインは腫瘍表面抗原CD19に対する一本鎖抗体であり、前記共刺激シグナル伝達領域はCD27シグナル伝達ドメインを含み、かつ前記誘導性自殺融合ドメインはiCasp9である、キメラ抗原受容体。 - 前記腫瘍表面抗原CD19に対する一本鎖抗体は、配列番号1に示されるアミノ酸配列又は該アミノ酸配列に対して90%を超えるホモロジーを有するアミノ酸配列を有し、
前記CD27シグナル伝達ドメインは、配列番号2に示されるアミノ酸配列を有し、かつ、
前記誘導性自殺融合ドメインiCasp9は、配列番号3に示されるアミノ酸配列を有する、請求項1に記載のキメラ抗原受容体。 - 前記誘導性自殺融合ドメインは、2A配列を介してCD3ζシグナル伝達ドメインとタンデムに連結されている、請求項2に記載のキメラ抗原受容体。
- 前記膜貫通ドメインは、CD28膜貫通ドメイン及び/又はCD8α膜貫通ドメインである、請求項1〜3のいずれか一項に記載のキメラ抗原受容体。
- 前記共刺激シグナル伝達領域は、CD28シグナル伝達ドメインを更に含む、請求項4に記載のキメラ抗原受容体。
- 前記キメラ抗原受容体は、シグナルペプチドと、抗原結合ドメインと、膜貫通ドメインと、共刺激シグナル伝達ドメインと、CD3ζシグナル伝達ドメインと、2A配列と、誘導性自殺融合ドメインとをタンデム配置で含む、請求項1〜5のいずれか一項に記載のキメラ抗原受容体。
- 前記キメラ抗原受容体は、タンデム配置での、分泌シグナルペプチド、CD19抗原結合ドメイン、CD8α及び/又はCD28膜貫通ドメイン、CD28細胞外シグナル伝達ドメイン、CD28細胞内シグナル伝達ドメイン、CD27細胞内シグナル伝達ドメイン、CD3ζ細胞内シグナル伝達ドメイン、2A配列、並びにiCasp9ドメインである、請求項6に記載のキメラ抗原受容体。
- 前記キメラ抗原受容体は、分泌−CD19−CD28−CD27−CD3ζ−2A−iCasp9であり、かつ、
分泌−CD19−CD28−CD27−CD3ζ−2A−iCasp9の前記キメラ抗原受容体は、配列番号4に示されるアミノ酸配列又は該アミノ酸配列に対して80%を超えるホモロジーを有するアミノ酸配列を有する、又は、
分泌−CD19−CD28−CD27−CD3ζ−2A−iCasp9の前記キメラ抗原受容体は、配列番号5に示される核酸配列又は該核酸配列に対して80%を超えるホモロジーを有する核酸配列を有する、請求項1〜7のいずれか一項に記載のキメラ抗原受容体。 - 前記キメラ抗原受容体は、該キメラ抗原受容体をコードする核酸配列による発現のためにT細胞へと形質導入され、
好ましくは、前記形質導入は、ウイルスベクター、真核性発現プラスミド若しくはmRNA配列のいずれか1つ、又はこれらの少なくとも2つの組合せを介して行われて、T細胞へとトランスフェクションされ、好ましくはウイルスベクターを介してT細胞へとトランスフェクションされ、
好ましくは、前記ウイルスベクターは、レンチウイルスベクター若しくはレトロウイルスベクターのいずれか1つ、又はこれらの少なくとも2つの組合せ、好ましくはレンチウイルスベクターである、請求項1〜8のいずれか一項に記載のキメラ抗原受容体。 - 哺乳動物細胞を、請求項1〜9のいずれか一項に記載のキメラ抗原受容体を含むウイルスベクターとパッケージングヘルパープラスミドpNHP及びpHEF−VSVGとで同時トランスフェクションすることによって得られる、組換えレンチウイルス。
- 前記哺乳動物細胞は、293細胞、293T細胞若しくはTE671細胞のいずれか1つ、又はこれらの少なくとも2つの組合せである、請求項10に記載の組換えレンチウイルス。
- 請求項1〜9のいずれか一項に記載のキメラ抗原受容体及び/又は請求項10若しくは11に記載の組換えレンチウイルスを含むT細胞。
- 請求項1〜9のいずれか一項に記載のキメラ抗原受容体、請求項10若しくは11に記載の組換えレンチウイルス、又は請求項12に記載のT細胞のいずれか1つ、又はこれらの少なくとも2つの組合せを含む組成物。
- キメラ抗原受容体T細胞の作製における、請求項1〜9のいずれか一項に記載のキメラ抗原受容体、請求項10若しくは11に記載の組換えレンチウイルス、又は請求項12に記載の組成物の使用、及び腫瘍治療薬におけるその利用。
- 前記腫瘍は、血液関連腫瘍性疾患であり、
好ましくは、前記血液関連腫瘍性疾患は、白血病又はリンパ腫から選択される、請求項14に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810155428.1 | 2018-02-23 | ||
CN201810155428.1A CN108383914A (zh) | 2018-02-23 | 2018-02-23 | 一种基于cd19的嵌合抗原受体及其应用 |
PCT/CN2019/076050 WO2019161796A1 (en) | 2018-02-23 | 2019-02-25 | A cd19-based chimeric antigen receptor and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021516256A true JP2021516256A (ja) | 2021-07-01 |
JP7059405B2 JP7059405B2 (ja) | 2022-04-25 |
Family
ID=63069289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020568017A Active JP7059405B2 (ja) | 2018-02-23 | 2019-02-25 | Cd19に基づくキメラ抗原受容体及びその利用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20200392248A1 (ja) |
EP (1) | EP3740511A4 (ja) |
JP (1) | JP7059405B2 (ja) |
CN (1) | CN108383914A (ja) |
WO (1) | WO2019161796A1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108383914A (zh) * | 2018-02-23 | 2018-08-10 | 北京美康基免生物科技有限公司 | 一种基于cd19的嵌合抗原受体及其应用 |
CN109880802B (zh) * | 2018-11-30 | 2022-12-13 | 北京美康基免生物科技有限公司 | 一种基于cd19和cd70的双重嵌合抗原受体基因修饰的免疫细胞及其应用 |
CN110951689A (zh) * | 2018-11-30 | 2020-04-03 | 北京美康基免生物科技有限公司 | 一种基于cd19和cd30的双重嵌合抗原受体基因修饰的免疫细胞及其应用 |
CN109517799B (zh) * | 2018-11-30 | 2022-07-26 | 北京美康基免生物科技有限公司 | 一种基于cd19和cd22的双重嵌合抗原受体基因修饰的免疫细胞及其应用 |
CN109468284A (zh) * | 2018-11-30 | 2019-03-15 | 北京美康基免生物科技有限公司 | 一种基于cd19和psma的双重嵌合抗原受体基因修饰的免疫细胞及其应用 |
CN109468283A (zh) * | 2018-11-30 | 2019-03-15 | 北京美康基免生物科技有限公司 | 一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用 |
CN109735558B (zh) * | 2018-12-12 | 2022-04-15 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
CN113330038A (zh) * | 2019-01-22 | 2021-08-31 | 亘喜生物科技(上海)有限公司 | Cd20组合靶向的工程化免疫细胞 |
CN109734813B (zh) * | 2019-01-28 | 2022-06-17 | 广东昭泰体内生物医药科技有限公司 | 一种嵌合抗原受体及其应用 |
EP3938387A1 (en) * | 2019-03-15 | 2022-01-19 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy |
CN111825769B (zh) * | 2019-04-16 | 2022-03-25 | 上海科技大学 | 一种泛素化缺失的嵌合抗原受体及其用途 |
CN111944062B (zh) * | 2019-12-09 | 2023-11-07 | 深圳市体内生物医药科技有限公司 | 一种识别Fc片段的嵌合抗原受体及其应用 |
CN111748044B (zh) * | 2020-07-31 | 2022-02-18 | 广东昭泰体内生物医药科技有限公司 | Cd19和pd-l1双靶点嵌合抗原受体及其应用 |
WO2022031597A1 (en) | 2020-08-03 | 2022-02-10 | Kyverna Therapeutics, Inc. | Methods of producing t regulatory cells, methods of transducing t cells, and uses of the same |
TW202242117A (zh) | 2020-12-30 | 2022-11-01 | 美商亞勞諾斯醫療公司 | 包含多順反子表現卡匣之重組載體及其使用方法 |
WO2022165419A1 (en) | 2021-02-01 | 2022-08-04 | Kyverna Therapeutics, Inc. | Methods for increasing t-cell function |
AU2022280063A1 (en) * | 2021-05-26 | 2024-01-04 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor to target hla-g-positive cancers |
CN114456270B (zh) * | 2022-03-02 | 2023-12-22 | 北京美康基免生物科技有限公司 | 一种gd2嵌合抗原受体及其应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170137515A1 (en) * | 2014-05-23 | 2017-05-18 | University Of Florida Research Foundation, Inc. | Car based immunotherapy |
JP2017518037A (ja) * | 2014-04-10 | 2017-07-06 | シアトル チルドレンズ ホスピタル, ディービーエー シアトル チルドレンズ リサーチ インスティテュート | 導入遺伝子の遺伝子タグおよびその使用方法 |
CN107245106A (zh) * | 2017-07-18 | 2017-10-13 | 深圳市免疫基因治疗研究院 | 一种基于cd10的嵌合抗原受体及其应用 |
CN107245107A (zh) * | 2017-07-18 | 2017-10-13 | 深圳市免疫基因治疗研究院 | 一种基于cd20的嵌合抗原受体及其应用 |
CN107312098A (zh) * | 2017-07-18 | 2017-11-03 | 深圳市免疫基因治疗研究院 | 一种基于cd22的嵌合抗原受体及其应用 |
CN107312097A (zh) * | 2017-07-18 | 2017-11-03 | 深圳市免疫基因治疗研究院 | 一种基于cd30的嵌合抗原受体及其应用 |
CN107337737A (zh) * | 2017-07-18 | 2017-11-10 | 深圳市免疫基因治疗研究院 | 一种嵌合抗原受体及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040002158A1 (en) * | 2002-06-05 | 2004-01-01 | Lung-Ji Chang | Long term expression of lentiviral vectors |
KR102542533B1 (ko) * | 2016-04-14 | 2023-06-13 | 프레드 허친슨 캔서 센터 | 표적화 핵산 나노수송체를 이용하여 치료 세포를 프로그램화하기 위한 조성물 및 방법 |
CN107312091B (zh) * | 2017-05-02 | 2019-10-22 | 重庆精准生物技术有限公司 | 靶向人cd19抗原的人源化单克隆抗体 |
CN107400168B (zh) * | 2017-07-18 | 2020-02-07 | 深圳市免疫基因治疗研究院 | 一种基于cd117的嵌合抗原受体及其应用 |
CN108383914A (zh) * | 2018-02-23 | 2018-08-10 | 北京美康基免生物科技有限公司 | 一种基于cd19的嵌合抗原受体及其应用 |
-
2018
- 2018-02-23 CN CN201810155428.1A patent/CN108383914A/zh active Pending
-
2019
- 2019-02-25 US US16/971,971 patent/US20200392248A1/en active Pending
- 2019-02-25 EP EP19757649.9A patent/EP3740511A4/en active Pending
- 2019-02-25 WO PCT/CN2019/076050 patent/WO2019161796A1/en unknown
- 2019-02-25 JP JP2020568017A patent/JP7059405B2/ja active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017518037A (ja) * | 2014-04-10 | 2017-07-06 | シアトル チルドレンズ ホスピタル, ディービーエー シアトル チルドレンズ リサーチ インスティテュート | 導入遺伝子の遺伝子タグおよびその使用方法 |
US20170137515A1 (en) * | 2014-05-23 | 2017-05-18 | University Of Florida Research Foundation, Inc. | Car based immunotherapy |
CN107245106A (zh) * | 2017-07-18 | 2017-10-13 | 深圳市免疫基因治疗研究院 | 一种基于cd10的嵌合抗原受体及其应用 |
CN107245107A (zh) * | 2017-07-18 | 2017-10-13 | 深圳市免疫基因治疗研究院 | 一种基于cd20的嵌合抗原受体及其应用 |
CN107312098A (zh) * | 2017-07-18 | 2017-11-03 | 深圳市免疫基因治疗研究院 | 一种基于cd22的嵌合抗原受体及其应用 |
CN107312097A (zh) * | 2017-07-18 | 2017-11-03 | 深圳市免疫基因治疗研究院 | 一种基于cd30的嵌合抗原受体及其应用 |
CN107337737A (zh) * | 2017-07-18 | 2017-11-10 | 深圳市免疫基因治疗研究院 | 一种嵌合抗原受体及其应用 |
Also Published As
Publication number | Publication date |
---|---|
JP7059405B2 (ja) | 2022-04-25 |
WO2019161796A1 (en) | 2019-08-29 |
EP3740511A1 (en) | 2020-11-25 |
EP3740511A4 (en) | 2021-11-17 |
CN108383914A (zh) | 2018-08-10 |
US20200392248A1 (en) | 2020-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7059405B2 (ja) | Cd19に基づくキメラ抗原受容体及びその利用 | |
JP7062720B2 (ja) | 細胞免疫療法のための方法および組成物 | |
AU2018204208B2 (en) | Method and compositions for cellular immunotherapy | |
EP3194432B1 (en) | Ror1 specific multi-chain chimeric antigen receptor | |
WO2020108644A1 (en) | Cd19-and cd22-based combined car-t immunotherapy | |
WO2020108643A1 (en) | Cd19-and cd70-based combined car-t immunotherapy | |
JP7158075B2 (ja) | Gd2に基づくキメラ抗原受容体及びその利用 | |
WO2020108645A1 (en) | Cd19-and bcma-based combined car-t immunotherapy | |
KR20200120939A (ko) | 변형된 만능성 줄기 세포, 및 제조 및 사용 방법 | |
WO2020108646A1 (en) | Cd19-and psma-based combined car-t immunotherapy | |
US20220096546A1 (en) | Modified Cell Expansion and Uses Thereof | |
WO2020108642A1 (en) | Cd19-and cd30-based combined car-t immunotherapy | |
US20210137983A1 (en) | Nk cell expansion and uses thereof | |
WO2023165517A1 (en) | Gd2 chimeric antigen receptor and use thereof | |
WO2022257835A1 (en) | Cd7-based humanized chimeric antigen receptor and use thereof | |
CN110819596A (zh) | 具有增强的迁移能力的修饰的细胞 | |
US11672827B2 (en) | Pharmaceutical chimeric receptor composition and method thereof | |
CA3125646A1 (en) | Modified cell expansion and uses thereof | |
AU2015295348B2 (en) | ROR1 specific multi-chain chimeric antigen receptor | |
JP2022531814A (ja) | 改変細胞の増幅およびその応用 | |
CN116426484A (zh) | 嵌合抗原受体t细胞群、组合物及其用途 | |
AU2015295348A1 (en) | ROR1 specific multi-chain chimeric antigen receptor | |
NZ726162B2 (en) | Method and compositions for cellular immunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200821 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210817 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211117 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220315 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220413 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7059405 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |